Adalimumab in Crohn's disease patients: Pharmacokinetics in the first 6 months of treatment

Alimentary Pharmacology and Therapeutics

Volumn 40, Issue 10, 2014, Pages 1202-1208

  Lie, M R K L ^a   Peppelenbosch, M P ^a   West, R L ^b   Zelinkova, Z ^a,c   Van Der Woude, C J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b SINT FRANCISCUS GASTHUIS   (Netherlands)

^c Bratislava   (Slovakia)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIINFLAMMATORY AGENT; C REACTIVE PROTEIN; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CHILD; COHORT ANALYSIS; CROHN DISEASE; DRUG BLOOD LEVEL; FEMALE; FOLLOW UP; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; SCHOOL CHILD; TERTIARY CARE CENTER; ADOLESCENT; ANTAGONISTS AND INHIBITORS; BLOOD; BODY MASS; DRUG COMBINATION; MIDDLE AGED; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; BODY MASS INDEX; C-REACTIVE PROTEIN; CROHN DISEASE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84908359992     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12969     Document Type: Article

References (35)

1. Papadakis KA, Targan SR,. Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology 2000; 119: 1148-57.
2. Van Deventer SJ,. Tumour necrosis factor and Crohn's disease. Gut 1997; 40: 443-8.
3. Targan SR, Hanauer SB, van Deventer SJ, et al,. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337: 1029-35.
4. Hanauer SB, Feagan BG, Lichtenstein GR, et al,. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-9.
5. Sands BE, Anderson FH, Bernstein CN, et al,. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004; 26: 876-85.
6. Present DH, Rutgeerts P, Targan S, et al,. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 6: 1398-405.
7. Rutgeerts P, D'Haens G, Targan S, et al,. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999; 117: 761-9.
8. Dewint P, Hansen BE, Verhey E, et al,. Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised double-blind placebo controlled trial (ADAFI). Gut 2014; 63: 292-9.
9. Baert F, Noman M, Vermeire S, et al,. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348: 601-8.
10. Farrell RJ, Alsahli M, Jeen YT, et al,. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 2003; 124: 917-24.
11. Hanauer SB, Wagner CL, Bala M, et al,. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004; 2: 542-53.
12. Cheifetz A, Smedley M, Martin S, et al,. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 2003; 98: 1315-24.
13. Steenholdt C, Bendtzen K, Brynskov J, et al,. Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease. Scand J Gastroenterol 2011; 46: 310-8.
14. Hanauer SB, Sandborn WJ, Rutgeerts P, et al,. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006; 130: 323-33.
15. Sandborn WJ, Hanauer SB, Rutgeerts P, et al,. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007; 56: 1232-9.
16. Colombel JF, Sandborn WJ, Rutgeerts P, et al,. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132: 52-6.
17. Sandborn WJ, Rutgeerts P, Enns R, et al,. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007; 146: 829-38.
18. Karmiris K, Paintoud G, Noman M, et al,. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 2009; 137: 1628-40.
19. Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al,. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007; 66: 921-6.
20. Zelinkova Z, De Haar C, De Ridder L, et al,. High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy. Aliment Pharmacol Ther 2011; 33: 1053-8.
21. Cohen S, Freeman T,. Metabolic heterogeneity of human gamma-globulin. Biochem J 1960; 76: 475-87.
22. Mazor Y, Kopylov U, Ben Hur D, et al,. Evaluating adalimumab drug and antibody levels as predictors of clinical and laboratory response in Crohn's disease patients. Gastroenterology 2013; 144: S778.
23. Roblin X, Marotte H, Rinaudo M, et al,. Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 2014; 12: 80-4.
24. Imaeda H, Takahashi K, Fujimoto T, et al,. Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn's disease. J Gastroenterol 2014; 49: 100-9.
25. Velayos F, Sheibani S, Lockton S, et al,. Prevalence of antibodies to adalimumab (ATA) and Correlation between ATA and low serum drug concentrations on CRP and clinical symptoms in a prospective sample of IBD patients. Gastroenterology 2013; 144: S91.
26. Weisman MH, Moreland LW, Furst DE, et al,. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Ther 2003; 25: 1700-21.
27. Chiu YL, Rubin DT, Vermeire S, et al,. Serum adalimumab concentration and clinical remission in patients with Crohn's Disease. Inflamm Bowel Dis 2013; 19: 1112-22.
28. Bultman E, de Haar C, van Liere-Baron A, et al,. Predictors of dose escalation of adalimumab in a prospective cohort of Crohn's disease patients. Aliment Pharmacol Ther 2012; 35: 335-41.
29. Chen DY, Chen YM, Tsai WC, et al,. Significant associations of antidrug antibody levels with serum drug trough levels and therapeutic response of adalimumab and etanercept treatment in rheumatoid arthritis. Ann Rheum Dis 2014. doi: 10.1136/annrheumdis-2013-203893 [Epub ahead of print].
30. Imagawa T, Takei S, Umebayashi H, et al,. Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan. Clin Rheumatol 2012; 31: 1713-21.
31. Kobayashi S, Harigai M, Mozaffarian N, et al,. A multicenter, open-label, efficacy, pharmacokinetic, and safety study of adalimumab in Japanese patients with ankylosing spondylitis. Mod Rheumatol 2012; 22: 589-97.
32. Bartelds GM, Krieckaert CL, Nurmohamed MT, et al,. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011; 305: 1460-8.
33. Arends S, Brouwer E, van der Veer E, et al,. Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study. Arthritis Res Ther 2011; 13: R94.
34. Nuij VJ, Zelinkova Z, Rijk MC, et al,.; for the Dutch Delta IBD Group. Phenotype of inflammatory bowel disease at diagnosis in the Netherlands: a population-based inception cohort study (the Delta Cohort). Inflamm Bowel Dis 2013; 19: 2215-22.
35. Bodini G, Savarino V, Fazio V, et al,. Relationship between drug serum concentration and clinical activity in patients with Crohn's disease who achieved remission with adalimumab. Dig Liver Dis 2012; 44: S69-70.